Industry Experience

Senior Contracts Analyst, Legal Department

Shire Human Genetic Therapies, Inc.

Associate Director of Contracts

Sepracor, Inc. (now Sunovion Pharmaceuticals)

Contracts Manager

Parexel

Sally has a wealth of experience in drafting and negotiating a broad range of contracts from more than fifteen years in the pharmaceutical and biotech industries. She is adept at managing the wide range of agreements required to support complex, global clinical studies (Phases I – IV). 

Sally also has expertise in preclinical research, master services, consulting, and preferred provider agreements, software licenses, and other contracts necessary for the development, manufacture and commercialization of pharmaceutical and other products. She is skilled in developing contract templates that are tailored to meet unique business, legal and regulatory requirements. In addition, she often assists clients with training to promote efficient contract processes and best practices.

experience +

experience –

Sally’s industry experience is extensive. She was a Senior Contracts Analyst in the Legal Department at Shire Human Genetic Therapies, Inc. and Associate Director of Contracts in the Legal Department at Sepracor Inc. (now Sunovion Pharmaceuticals), where she drafted and negotiated a broad range of contracts for research, development, clinical, and commercial operations.

Earlier in her career, Sally was the Contract Manager in the Legal Department at Parexel, a global CRO for the pharmaceutical industry. She managed a team of contract analysts and finalized a variety of research and drug development agreements on behalf of Parexel’s client companies, including multi-site, global clinical trial agreements.

Recent Client Work +

Recent Client WOrk –

  • Phase 3 clinical trial sponsored by Paratek Pharmaceuticals, Inc. involving approximately 650 subjects across 100 sites in the US, Europe, Latin America, Israel, South Africa and Taiwan
  • Phase 3 clinical trial sponsored by Paratek Pharmaceuticals, Inc. involving approximately 750 subjects across 150 sites in the US and Europe, Latin America, Israel, South Africa and Taiwan
  • Phase 3 clinical trial sponsored by AVEO Pharmaceuticals, Inc. involving approximately 300 subjects across 175 sites in the US, Canada, Europe, Israel and Australia

Community +

Community –

Education
  • Tufts University, B.A., cum laude